GTX Genetix Grp

RNS Number:5010E
Genetix Group PLC
29 November 2002

                                  Board Change


New Milton Hampshire UK, 29 November 2002 -Genetix Group plc ("Genetix" or the 
"Company") announces that, at its Board meeting today, James Cochrane advised 
the Board of his intention to resign as a non-executive director of the Company 
with effect from 31 December 2002 due to other business commitments. The Company 
has commenced its search for a replacement non-executive director.

Mark Reid, CEO of Genetix, said: "We are very grateful for James' valuable help
and support over the past two years during which time Genetix has increased its
international market position and range of innovative products."


Genetix Group plc
Mark Reid, Chief Executive Officer                   Tel:  +44 (0) 1425 624600
Gary Corsi, Finance Director

Financial Dynamics
Jonathan Birt                                        Tel:  +44 (0) 7884 238 952


Notes to Editors

Genetix Group plc

Genetix Group plc provides automated systems and services for genomic and
proteomic research. It supplies many leading academic institutions world-wide
including the Max Planck Institute and major international companies involved in
the drug discovery process including GSK, AstraZeneca and Novartis. Genetix made
a significant contribution to the Human Genome Project by supplying
high-throughput equipment to seven of the leading eight laboratories of the
consortia. Genetix through its R&D expertise and scientific resource is
committed to the continual development of innovative solutions to accelerate the
rate of global scientific discovery. Genetix is quoted on the London Stock
Exchange and is based in New Milton, Hampshire, UK.  www.genetix.com


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

BOAEAKFNALAAFFE

Genetix Grp (LSE:GTX)
Historical Stock Chart
From Jun 2024 to Jul 2024

Genetix Grp (LSE:GTX)
Historical Stock Chart
From Jul 2023 to Jul 2024